<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LETROZOLE</span><br/>(le'tro-zole)<br/><span class="topboxtradename">Femara<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">aromatase inhibitor</span><br/><b>Prototype: </b>Anastrozole<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonsteroid competitive inhibitor of the enzyme system that converts androgens to estrogens.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Results in the regression of estrogen-dependent tumors.</p>
<h1><a name="uses">Uses</a></h1>
<p>Advanced breast cancer in postmenopausal women following antiestrogen therapy, first-line treatment of locally advanced or
         metastasized breast cancer in postmenopausal women.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to letrozole; pregnancy (category D).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate to severe hepatic impairment; lactation. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.5 mg q.d.<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Reduce the dose in severe hepatic impairment (Child-Pugh C Class) by 50%.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give without regard to food.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue, peripheral edema, asthenia, weight increase, <span class="speceff-common">musculoskeletal pain,</span> arthralgia. <span class="typehead">CNS:</span> Headache, somnolence, dizziness. <span class="typehead">CV:</span> Chest pain, hypertension, hypercholesterolemia. <span class="typehead">GI:</span> Nausea, vomiting, constipation, diarrhea, abdominal pain, anorexia, dyspepsia. <span class="typehead">Respiratory:</span> Dyspnea, cough. <span class="typehead">Skin:</span> Hot flushes, rash, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">estrogens</span>, <span class="classification">oral contraceptives</span> could interfere with the pharmacologic action of letrozole. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochromes P450 3A4 and 2A6. <span class="typehead">Elimination:</span> 90% excreted in urine. <span class="typehead">Half-Life:</span> 2 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Periodically monitor serum calcium and CBC with differential.</li>
<li>Monitor carefully for S&amp;S of thrombophlebitis or thromboembolism; report immediately.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician immediately if S&amp;S of thrombophlebitis develop (see Appendix F).</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>